for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

IDEXX Laboratories, Inc.

IDXX.O

Latest Trade

280.77USD

Change

-5.13(-1.79%)

Volume

345,231

Today's Range

279.18

 - 

289.25

52 Week Range

198.75

 - 

294.57

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
285.90
Open
288.21
Volume
345,231
3M AVG Volume
10.48
Today's High
289.25
Today's Low
279.18
52 Week High
294.57
52 Week Low
198.75
Shares Out (MIL)
85.89
Market Cap (MIL)
24,085.17
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q4 2019 IDEXX Laboratories Inc Earnings Release

Latest Developments

More

Idexx Laboratories Posts Q3 Earnings Per Share $1.24

IDEXX Laboratories Announces Second Quarter Results

Idexx Laboratories Chief Executive Officer Jonathan Ayers Takes Medical Leave Of Absence

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.

Contact Info

1 Idexx Dr

+1.207.5560300

https://www.idexx.com/

Executive Leadership

Lawrence D. Kingsley

Independent Chairman of the Board

Jonathan Jay Mazelsky

President, Chief Executive Officer

Brian P. McKeon

Chief Financial Officer, Executive Vice President, Treasurer

Giovani Twigge

Chief Human Resource Officer, Corporate Vice President

Sharon E. Underberg

Corporate Vice President, General Counsel, and Corporate Secretary

Key Stats

1.88 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

1.8K

2017

2.0K

2018

2.2K

2019(E)

2.4K
EPS (USD)

2016

2.440

2017

3.280

2018

4.260

2019(E)

4.777
Price To Earnings (TTM)
57.91
Price To Sales (TTM)
10.25
Price To Book (MRQ)
119.13
Price To Cash Flow (TTM)
47.13
Total Debt To Equity (MRQ)
409.53
LT Debt To Equity (MRQ)
296.15
Return on Investment (TTM)
44.52
Return on Equity (TTM)
25.79

Latest News

Latest News

BRIEF-Idexx Laboratories Reports Q1 Earnings Per Share $1.01

* Q1 EARNINGS PER SHARE VIEW $0.92 -- THOMSON REUTERS I/B/E/S

BRIEF-IDEXX Laboratories Reports Q4 Earnings Per Share $0.43

* IDEXX LABORATORIES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 RESULTS

BRIEF-IDEXX To Introduce Applied Biocode's Innovative Multiplex Technology Across Global Reference Laboratory Network

* IDEXX TO INTRODUCE APPLIED BIOCODE'S INNOVATIVE MULTIPLEX TECHNOLOGY ACROSS GLOBAL REFERENCE LABORATORY NETWORK

BRIEF-Idexx Laboratories Announces Estimated Impact Of U.S. Tax Reform

* IDEXX LABORATORIES ANNOUNCES ESTIMATED IMPACT OF U.S. TAX REFORM

BRIEF-IDEXX Laboratories Q3 earnings per share $0.79

* Q3 earnings per share view $0.74 -- Thomson Reuters I/B/E/S

BRIEF-Idexx Laboratories reports Q2 EPS $0.95

* Sees fy 2017 earnings per share $3.12 to $3.22 including items

BRIEF-Idexx Laboratories elects Stuart Essig to the board

* Idexx Laboratories elects Stuart M. Essig to board of directors

BRIEF-Idexx Labs director End sells 5,000 shares of co's common stock on May 22

* Idexx Laboratories director William End reports sale of 5,000 shares of co's common stock on May 22 at average price of $162.55 per share - SEC filing Source text: http://bit.ly/2qSclJO Further company coverage:

BRIEF-Idexx Laboratories reports increase in share repurchase program

* To repurchase up to an additional 3.0 million shares of its common stock under its ongoing share repurchase program

BRIEF-Idexx Laboratories reports Q1 EPS $0.77

* Says increases 2017 eps outlook range by $0.10 to $2.95 - $3.11

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up